Abstract
The non-nucleoside reverse transcriptase inhibitor (NNRTI) nevirapine (NVP) has been used as a component of salvage therapy for patients who have experienced virologic failure while taking nucleosides and protease inhibitors (PIs). In spite of broad cross-resistance within the NNRTI class, NVP may also play a role in salvage therapy for patients who have experienced failure while taking NNRTIs Another role for NVP in treatment-experienced patients is in so-called "PI switch" strategies, in which NVP is substituted for a PI within a virologically successful combination regimen. This paper reviews the clinical data that support the use of NVP in salvage regimens and PI switch strategies.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of acquired immune deficiency syndromes (1999)
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
